|
1
|
Binefa G, Rodríguez-Moranta F, Teule A and
Medina-Hayas M: Colorectal cancer: From prevention to personalized
medicine. World J Gastroenterol. 20:6786–6808. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC,
Zhu DX and Xu JM: Anti-EGFR and anti-VEGF agents: Important
targeted therapies of colorectal liver metastases. World J
Gastroenterol. 20:4263–4275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Banjerdpongchai R, Chanwikruy Y,
Rattanapanone V and Sripanidkulchai B: Induction of apoptosis in
the human leukemic U937 cell line by Kaempferia parviflora
Wall.ex.Baker extract and effects of paclitaxel and camptothecin.
Asian Pac J Cancer Prev. 10:1137–1140. 2009.PubMed/NCBI
|
|
4
|
Yan YX, Li WZ, Huang YQ and Liao WX: The
COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral
cancer cell lines to Vincristine by down-regulating P-glycoprotein
expression and function. Prostaglandins Other Lipid Mediat.
97:29–35. 2012. View Article : Google Scholar
|
|
5
|
Weaver BA: How Taxol/paclitaxel kills
cancer cells. Mol Biol Cell. 25:2677–2681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Das S, Santani DD and Dhalla NS:
Experimental evidence for the cardioprotective effects of red wine.
Exp Clin Cardiol. 12:5–10. 2007.
|
|
7
|
Thomasset SC, Berry DP, Garcea G, Marczylo
T, Steward WP and Gescher AJ: Dietary polyphenolic phytochemicals –
promising cancer chemopreventive agents in humans? A review of
their clinical properties. Int J Cancer. 120:451–458. 2007.
View Article : Google Scholar
|
|
8
|
Gehm BD, McAndrews JM, Chien PY and
Jameson JL: Resveratrol, a polyphenolic compound found in grapes
and wine, is an agonist for the estrogen receptor. Proc Natl Acad
Sci USA. 94:14138–14143. 1997. View Article : Google Scholar
|
|
9
|
Cottart CH, Nivet-Antoine V and Beaudeux
JL: Review of recent data on the metabolism, biological effects,
and toxicity of resveratrol in humans. Mol Nutr Food Res. 58:7–21.
2014. View Article : Google Scholar
|
|
10
|
Liu YZ, Wu K, Huang J, Liu Y, Wang X, Meng
ZJ, Yuan SX, Wang DX, Luo JY, Zuo GW, et al: The PTEN/PI3K/Akt and
Wnt/β-catenin signaling pathways are involved in the inhibitory
effect of resveratrol on human colon cancer cell proliferation. Int
J Oncol. 45:104–112. 2014.PubMed/NCBI
|
|
11
|
Chin YT, Hsieh MT, Yang SH, Tsai PW, Wang
SH, Wang CC, Lee YS, Cheng GY, HuangFu WC, London D, et al:
Antiproliferative and gene expression actions of resveratrol in
breast cancer cells in vitro. Oncotarget. 5:12891–12907. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kai L, Samuel SK and Levenson AS:
Resveratrol enhances p53 acetylation and apoptosis in prostate
cancer by inhibiting MTA1/NuRD complex. Int J Cancer.
126:1538–1548. 2010.
|
|
13
|
Sánchez-Duffhues G, Hiepen C, Knaus P and
Ten Dijke P: Bone morphogenetic protein signaling in bone
homeostasis. Bone. 80:43–59. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen D, Zhao M, Harris SE and Mi Z: Signal
transduction and biological functions of bone morphogenetic
proteins. Front Biosci. 9:349–358. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Duan L, Ye L, Wu R, Wang H, Li X, Li H,
Yuan S, Zha H, Sun H, Zhang Y, et al: Inactivation of the
phosphatidylinositol 3-kinase/Akt pathway is involved in
BMP9-mediated tumor-suppressive effects in gastric cancer cells. J
Cell Biochem. 116:1080–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Epstein NE: Basic science and spine
literature document bone morphogenetic protein increases cancer
risk. Surg Neurol Int. 5(Suppl 15): S552–S560. 2014. View Article : Google Scholar
|
|
17
|
Toofan P, Irvine D, Hopcroft L, Copland M
and Wheadon H: The role of the bone morphogenetic proteins in
leukaemic stem cell persistence. Biochem Soc Trans. 42:809–815.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang JH, Liu YZ, Yin LJ, Chen L, Huang J,
Liu Y, Zhang RX, Zhou LY, Yang QJ, Luo JY, et al: BMP9 and COX-2
form an important regulatory loop in BMP9-induced osteogenic
differentiation of mesenchymal stem cells. Bone. 57:311–321. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang K, Feng H, Ren W, Sun X, Luo J, Tang
M, Zhou L, Weng Y, He TC and Zhang Y: BMP9 inhibits the
proliferation and invasiveness of breast cancer cells MDA-MB-231. J
Cancer Res Clin Oncol. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye L, Kynaston H and Jiang WG: Bone
morphogenetic protein-9 induces apoptosis in prostate cancer cells,
the role of prostate apoptosis response-4. Mol Cancer Res.
6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Luo X, Chen J, Song WX, Tang N, Luo J,
Deng ZL, Sharff KA, He G, Bi Y, He BC, et al: Osteogenic BMPs
promote tumor growth of human osteosarcomas that harbor
differentiation defects. Lab Invest. 88:1264–1277. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herrera B, van Dinther M, Ten Dijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptorlike kinase-2/Smad1/Smad4 to promote ovarian cancer
cell proliferation. Cancer Res. 69:9254–9262. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Herrera B, García-Álvaro M, Cruz S, Walsh
P, Fernández M, Roncero C, Fabregat I, Sánchez A and Inman GJ: BMP9
is a proliferative and survival factor for human hepatocellular
carcinoma cells. PLoS One. 8:e695352013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lv Z, Wang C, Yuan T, Liu Y, Song T, Liu
Y, Chen C, Yang M, Tang Z, Shi Q, et al: Bone morphogenetic protein
9 regulates tumor growth of osteosarcoma cells through the
Wnt/β-catenin pathway. Oncol Rep. 31:989–994. 2014.
|
|
26
|
Huang J, Yuan SX, Wang DX, Wu QX, Wang X,
Pi CJ, Zou X, Chen L, Ying LJ, Wu K, et al: The role of COX-2 in
mediating the effect of PTEN on BMP9 induced osteogenic
differentiation in mouse embryonic fibroblasts. Biomaterials.
35:9649–9659. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhao Y, Song T, Wang W, Wang J, He J, Wu
N, Tang M, He B and Luo J: P38 and ERK1/2 MAPKs act in opposition
to regulate BMP9-induced osteogenic differentiation of mesenchymal
progenitor cells. PLoS One. 7:e433832012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cuadrado A and Nebreda AR: Mechanisms and
functions of p38 MAPK signalling. Biochem J. 429:403–417. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He TC, Zhou S, da Costa LT, Yu J, Kinzler
KW and Vogelstein B: A simplified system for generating recombinant
adenoviruses. Proc Natl Acad Sci USA. 95:2509–2514. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim
SH, Huang E, Gao Y, Yang K, Wagner ER, et al: Tetrandrine inhibits
Wnt/β-catenin signaling and suppresses tumor growth of human
colorectal cancer. Mol Pharmacol. 79:211–219. 2011. View Article : Google Scholar :
|
|
32
|
Chen CS, Ho DR, Chen FY, Chen CR, Ke YD
and Su JG: AKT mediates actinomycin D-induced p53 expression.
Oncotarget. 5:693–703. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tárraga López PJ, Albero JS and
Rodríguez-Montes JA: Primary and secondary prevention of colorectal
cancer. Clin Med Insights Gastroenterol. 7:33–46. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aggarwal S and Chu E: Current therapies
for advanced colorectal cancer. Oncology. 19:589–595.
2005.PubMed/NCBI
|
|
35
|
Wolpin BM and Bass AJ: Managing advanced
colorectal cancer: Have we reached the PEAK with current therapies?
J Clin Oncol. 32:2200–2202. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tol J and Punt CJ: Monoclonal antibodies
in the treatment of metastatic colorectal cancer: A review. Clin
Ther. 32:437–453. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khazir J, Riley DL, Pilcher LA, De-Maayer
P and Mir BA: Anticancer agents from diverse natural sources. Nat
Prod Commun. 9:1655–1669. 2014.PubMed/NCBI
|
|
38
|
Boocock DJ, Faust GE, Patel KR, Schinas
AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher
AJ, et al: Phase I dose escalation pharmacokinetic study in healthy
volunteers of resveratrol, a potential cancer chemopreventive
agent. Cancer Epidemiol Biomarkers Prev. 16:1246–1252. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vanamala J, Reddivari L, Radhakrishnan S
and Tarver C: Resveratrol suppresses IGF-1 induced human colon
cancer cell proliferation and elevates apoptosis via suppression of
IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer.
10:2382010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sheth S, Jajoo S, Kaur T, Mukherjea D,
Sheehan K, Rybak LP and Ramkumar V: Resveratrol reduces prostate
cancer growth and metastasis by inhibiting the Akt/MicroRNA-21
pathway. PLoS One. 7:e516552012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Parekh P, Motiwale L, Naik N and Rao KV:
Downregulation of cyclin D1 is associated with decreased levels of
p38 MAP kinases, Akt/PKB and Pak1 during chemopreventive effects of
resveratrol in liver cancer cells. Exp Toxicol Pathol. 63:167–173.
2011. View Article : Google Scholar
|
|
42
|
Gweon EJ and Kim SJ: Resveratrol induces
MMP-9 and cell migration via the p38 kinase and PI-3K pathways in
HT1080 human fibrosarcoma cells. Oncol Rep. 29:826–834. 2013.
|
|
43
|
Herrera B, Dooley S and Breitkopf-Heinlein
K: Potential roles of bone morphogenetic protein (BMP)-9 in human
liver diseases. Int J Mol Sci. 15:5199–5220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu Y, Liu Y, Zhang R, Wang X, Huang F,
Yan Z, Nie M, Huang J, Wang Y, Wang Y, et al: All-trans retinoic
acid modulates bone morphogenic protein 9-induced osteogenesis and
adipogenesis of preadipocytes through BMP/Smad and Wnt/β-catenin
signaling pathways. Int J Biochem Cell Biol. 47:47–56. 2014.
View Article : Google Scholar
|
|
45
|
Luo J, Tang M, Huang J, He BC, Gao JL,
Chen L, Zuo GW, Zhang W, Luo Q, Shi Q, et al: TGFbeta/BMP type I
receptors ALK1 and ALK2 are essential for BMP9-induced osteogenic
signaling in mesenchymal stem cells. J Biol Chem. 285:29588–29598.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sanvitale CE, Kerr G, Chaikuad A, Ramel
MC, Mohedas AH, Reichert S, Wang Y, Triffitt JT, Cuny GD, Yu PB, et
al: A new class of small molecule inhibitor of BMP signaling. PLoS
One. 8:e627212013. View Article : Google Scholar : PubMed/NCBI
|
